Giant Cell Arteritis in Combination with Posterior Capsular Cataract. Clinical Case
https://doi.org/10.18008/1816-5095-2025-3-625-631
Abstract
Giant cell arteritis (GCA) is an immune-mediated systemic granulomatous vasculitis that affects medium-sized and large arteries that have an internal elastic lamina. GCA occurs 3 times more often in women than in men because women are much more susceptible to autoimmune diseases, which can be caused by a number of biological factors, including the hormone estrogen. Data on the signs and symptoms of GCA are conflicting. Patients with GCA may complain of one or more of the following symptoms: headache, scalp tenderness, neck pain, malaise, myalgia, anorexia, weight loss, anemia, pain during chewing. Symptoms of polymyalgia rheumatica, temporal artery abnormalities, flu-like symptoms, fever of unknown etiology, and other unspecified systemic symptoms may also be present. Ischemic lesions that may develop in GCA include ischemic stroke, coronary arteritis and myocardial infarction, mesenteric lesions and scalp necrosis. Occult GCA is described, in which patients do not have systemic symptoms of this disease despite a positive temporal artery biopsy, increased ESR and CRP. Occult GCA is a potential cause of blindness. The review also describes the diagnostic criteria and ophthalmologic manifestations of GCA.
About the Authors
Yu. N. Yusef
M.M. Krasnov Research Institute of Eye Diseases
Russian Federation
Russian Federation
Yusef Naim Yusef - MD, director, Professor.
Rossolimo str., 11A, B, Moscow, 119021
E. E. Kazaryan
M.M. Krasnov Research Institute of Eye Diseases
Russian Federation
Russian Federation
Elina E. Kazaryan - MD, senior researcher of the Modern Treatment Methods in Ophthalmology Department.
Rossolimo str., 11A, B, Moscow, 119021
S. A. Shashorina
M.M. Krasnov Research Institute of Eye Diseases
Russian Federation
Russian Federation
Svetlana A. Shashorina - PhD, junior researcher of the Department of Modern Treatment Methods in Ophthalmology.
Rossolimo str., 11A, B, Moscow, 119021
References
1. Hutchinson J. Diseases of the arteries. On a peculiar form of thrombotic arteritis of the aged which is sometimes productive of gangrene Arch Surg (Lond). 1889;1890(1):323-329.
2. Schmidt M. Intracranial aneurysms Brain. 1930;53:489-540.
3. Horton BJ, Magath TB, Brown GE. An unusual form of arteritis of the temporal vessels Mayo Clin Proc. 1932;7:700-701.
4. Gilmour JR. Giant cell chronic arteritis J Pathol Bacteriol. 1941;53:263-277.
5. Borchers AT, Gershwin ME. Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment. Autoimmun Rev. 2012 May;11(6-7):A544-554. doi: 10.1016/j.autrev.2012.01.003.
6. Pepper K. Giant cell arteritis. Postgrad Med. 2023 Jan;135(sup1):22-32. doi: 10.1080/00325481.2023.2190288.
7. Thomas DC, Thomas P, Pillai DP, Joseph D, Lingaiah U, Mathai BC, Ravi A, Chhabra S, Pitchumani PK. Giant Cell Arteritis: A Case-Based Narrative Review of the Literature. Curr Pain Headache Rep. 2022 Oct;26(10):725-740. doi: 10.1007/s11916-022-01075-1.
8. Simmons RJ, Cogan DG. Occult temporal arteritis Arch Ophthalmol. 1962;68:8-18.
9. Hayreh SS Ischemic optic neuropathies. 2011 Heidelberg Springer-Verlag:163-264.
10. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, Ed-worthy SM, Fauci AS, Leavitt RY, Lie JT. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990 Aug;33(8):1122-1128. doi: 10.1002/art.1780330810.
11. Costello F, Zimmerman MB, Podhajsky PA, Hayreh SS. Role of thrombocytosis in diagnosis of giant cell arteritis and differentiation of arteritic from non-arteritic anterior ischemic optic neuropathy Eur J Ophthalmol. 2004;14:245-257. doi: 10.1177/112067210401400310.
12. Xia C, Edwards R, Omidvar B. A Case of Giant Cell Arteritis With a Normal Erythrocyte Sedimentation Rate (ESR) Post ChAdOx1 nCoV-19 Vaccination. Cureus. 2022 May 27;14(5):e25388. doi: 10.7759/cureus.25388.
13. Horton BT, Magath TB. Arteritis of the temporal vessels: Report of seven cases Proc Staff Meet Mayo Clin. 1937;12:548-553.
14. Jennings GH. Arteritis of the temporal vessels Lancet. 1938;1:424-428.
15. Chen Q, Chen W, Feng C, Gong D, Zhang J, Bi Y, Sun P, Sun X, Tian G. Giant Cell Arteritis Presenting With Ocular Symptoms: Clinical Characteristics and Multimodal Imaging in a Chinese Case Series. Front Med (Lausanne). 2022 Jun 20;9:885463. doi: 10.3389/fmed.2022.885463.
16. Kokloni IN, Aligianni SI, Makri O, Daoussis D. Vision loss in giant cell arteritis: case-based review. Rheumatol Int. 2022 Oct;42(10):1855-1862. doi: 10.1007/s00296-022-05160-x.
17. Saleh M, Turesson C, Englund M, Merkel PA, Mohammad AJ. Visual complications in patients with biopsy-proven giant cell arteritis: A population-based study J Rheumatol. 2016;43:1559-1565. doi: 10.3899/jrheum.151033.
18. Ji J, Dimitrijevic I, Sundquist J, Sundquist K, Zöller B. Risk of ocular manifestations in patients with giant cell arteritis: A nationwide study in Sweden Scand J Rheumatol. 2017;46:484-489. doi: 10.1080/03009742.2016.1266030.
19. Czihal M, Tschaidse J, Bernau C, Lottspeich C, Köhler A, Dechant C, et al Ocular ischaemic complications in giant cell arteritis: CHADS2-score predicts risk of permanent visual impairment Clin Exp Rheumatol. 2019;37(Suppl 117):61-64.
20. Hayreh SS. Giant cell arteritis: Its ophthalmic manifestations. Indian J Ophthalmol. 2021 Feb;69(2):227-235. doi: 10.4103/ijo.IJO_1681_20.
21. Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis Am J Ophthalmol. 1998;125:509-520. doi: 10.1016/s0002-9394(99)80192-5.
22. Biousse V, Newman NJ. Ischemic optic neuropathies. N Engl J Med. 2015;372:2428-2436. doi: 10.1056/NEJMx150042.
23. Hayreh SS. Anterior ischaemic optic neuropathy. II. Fundus on ophthalmoscopy and fluorescein angiography Br J Ophthalmol. 1974;58:964-980. doi: 10.1136/bjo.58.12.964.
24. Donaldson L, Margolin E. Vision loss in giant cell arteritis. Pract Neurol. 2022 Apr;22(2):138-140. doi: 10.1136/practneurol-2021-002972.
25. Yan Y, Li Z, Luo Y, Chen P, Liu L. Biopsy-Proven Giant Cell Arteritis Associated Vision Loss in Chinese Subjects: A Case Series and Review of the Literature. Neuroophthalmology. 2022 Aug 2;47(2):79-87. doi: 10.1080/01658107.2022.2099427.
26. Evangelatos G, Grivas A, Pappa M, Kouna K, Iliopoulos A, Fragoulis GE. Cranial giant cell arteritis mimickers: A masquerade to unveil. Autoimmun Rev. 2022 May;21(5):103083. doi: 10.1016/j.autrev.2022.103083.
27. Hayreh SS, Zimmerman B. Management of giant cell arteritis: Our 27-year clinical study; New light on old controversies Ophthalmologica. 2003;217:239-259. doi: 10.1159/000070631.
28. Dinkin M, Johnson E. One giant step for giant cell arteritis: updates in diagnosis and treatment. Curr Treat Options Neurol. 2021;23(2):6. doi: 10.1007/s11940-020-00660-2.
29. Hayreh SS. Treatment of acute visual loss in giant cell arteritis: Should we prescribe high-dose intravenous steroids or just oral steroids? J Neuro-Ophthalmol. 2012;32:278-287. doi: 10.1097/WNO.0b013e3182688218.
30. Tashiro T, Tsujimoto A, Nakamura N. [Ischemic optic neuropathy despite pulse methylprednisolone therapy in a giant cell arteritis patient with perineural optic nerve enhancement]. Rinsho Shinkeigaku. 2021 Dec 22;61(12):851-855. Japanese. doi: 10.5692/clinicalneurol.cn-001643.
31. Hunder GG, Sheps SG, Allen GL, Joyce JW. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: Comparison in a prospective study Ann Intern Med. 1975;82:613-618. doi: 10.7326/0003-4819-82-5-613.
32. Costello F, Zimmerman MB, Podhajsky PA, Hayreh SS. Role of thrombocytosis in diagnosis of giant cell arteritis and differentiation of arteritic from non-arte-ritic anterior ischemic optic neuropathy Eur J Ophthalmol. 2004;14:245-257. doi: 10.1177/112067210401400310.
33. Mollan S, Sharrack N, Burdon M, Denniston A. Aspirin as adjunctive treatment for giant cell arteritis. Cochrane Database. Syst Rev. 2014;8:CD010453. doi: 10.1002/14651858.CD010453.pub2.
34. Amsler J, Kysela I, Tappeiner C, Seitz L, Christ L, Scholz G, Stalder O, Kollert F, Reichenbach S, Villiger PM. Vision loss in patients with giant cell arteritis treated with tocilizumab. Arthritis Res Ther. 2021 Mar 22;23(1):92. doi: 10.1186/s13075-021-02480-4.
35. Spiera RF, Mitnick HJ, Kupersmith M, Richmond M, Spiera H, Peterson MG, Paget SA. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol. 2001 Sep-Oct;19(5):495-501.
36. Nguyen NV, Karkhur S, Yuksel M, Hassan M, Halim MS, Nguyen QD, Hasanreisoglu M. Posterior Uveitis Associated with Large Vessel Giant Cell Arteritis. Ocul Immunol Inflamm. 2022 Oct-Nov;30(7-8):2019-2022. doi: 10.1080/09273948.2021.1952274.
37. Hunter TG, Chong GT, Asrani S, Allingham RR, Blumberg DM. Simultaneous bilateral angle closure glaucoma in a patient with giant cell arteritis. J Glaucoma. 2010 Feb;19(2):149-150. doi: 10.1097/IJG.0b013e3181a98f03.
38. Fong JW, Chacko JG. Timing of cataract surgery in patients with giant cell arteritis. J Cataract Refract Surg. 2021 Jan 1;47(1):83-86. doi: 10.1097/j.jcrs.0000000000000392.
Review
For citations:
Yusef Yu.N., Kazaryan E.E., Shashorina S.A. Giant Cell Arteritis in Combination with Posterior Capsular Cataract. Clinical Case. Ophthalmology in Russia. 2025;22(3):625-631. (In Russ.) https://doi.org/10.18008/1816-5095-2025-3-625-631
Views:
9
Email this article 